News summary produced by Claude AI
An international clinical trial has demonstrated that finerenone, a medication previously studied mainly in diabetic populations, can meaningfully slow the progression of chronic kidney disease in non-diabetic patients. The FIND-CKD study, led by clinical pharmacologist Hiddo Lambers Heerspink of the University Medical Center Groningen and published in the New England Journal of Medicine, enrolled 1,584 adults with chronic kidney disease who showed impaired kidney function and elevated urinary protein levels.
The study followed participants for an average of just over three years, with half receiving daily finerenone and half receiving a placebo, while all continued standard treatment with ACE inhibitors or angiotensin receptor blockers. Researchers measured kidney function using estimated glomerular filtration rate, which indicates how effectively the kidneys filter waste. Those receiving finerenone experienced a statistically significant slowing in the decline of kidney function compared to the placebo group, with improvements that researchers characterized as clinically meaningful.
Beyond slowing kidney function decline, finerenone reduced the risk of serious health complications by approximately 23 percent. Among study participants, 13.9 percent in the finerenone group experienced major kidney events, heart failure hospitalization, or cardiovascular death, compared to 16.9 percent in the placebo group. The drug also produced a substantial reduction in urinary protein, with the finerenone group seeing an average decrease of over 41 percent compared to 9 percent in the placebo group, with more than half of treated patients achieving at least a 30 percent reduction.
The findings are significant because they expand finerenone’s potential use beyond diabetic patients to the broader non-diabetic chronic kidney disease population, which comprises more than half of all chronic kidney disease cases worldwide. With an estimated 800 million adults worldwide affected by chronic kidney disease and limited therapeutic options available for non-diabetic patients, the results suggest finerenone could address a substantial treatment gap. Researchers noted the drug was safe throughout the study period and could provide physicians with new tools to preserve kidney function and reduce complications in an underserved patient population.